ESC 365 - KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk

ESC2025 Premium Access

KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk

Session: HOT LINE 4

Topic: Pharmacotherapy

Speaker: Doctor N. Pagidipati (Durham, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Neha Pagidipati

Duke Clinical Research Institute, Durham (United States of America)

3 presentations

1 follower

11 more presentations in this session

BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

Speaker: Professor B. Williams (London, GB)

Discussant review - BaxHTN

Speaker: Professor T. Guzik (Edinburgh, GB)

Panel discussion - BaxHTN

Discussant review - KARDIA-3

Speaker: Professor M. Tomaszewski (Manchester, GB)

Panel discussion - KARDIA-3

Access the full session

HOT LINE 4

Speakers: Doctor N. Pagidipati, Professor B. Williams, Professor T. Guzik, Professor M. Tomaszewski

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources